The coming of age for antigen‐specific therapy of multiple sclerosis
- 20 July 2006
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 13 (8), 793-794
- https://doi.org/10.1111/j.1468-1331.2006.01532.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II‐defined cohort of patients with progressive multiple sclerosis: results of a 24‐month double‐blind placebo‐controlled clinical trial and 5 years of follow‐up treatmentEuropean Journal of Neurology, 2006
- Lipid microarrays identify key mediators of autoimmune brain inflammationNature Medicine, 2005
- Blocking adhesion molecules as therapy for multiple sclerosis: natalizumabNature Reviews Drug Discovery, 2005
- Design of effective immunotherapy for human autoimmunityNature, 2005
- Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosisMultiple Sclerosis Journal, 2005
- Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitisNature Biotechnology, 2003
- Altered Peptide Ligands and MS TreatmentScience, 2002
- Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.JCI Insight, 1997
- Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic proteinJournal of Neuroimmunology, 1988